Conference Day Two
Thursday, August 1 2024

8:00 am Morning Check-in & Light Breakfast

8:50 am Chair’s Opening Remarks

Maximizing the Therapeutic Potential of Radiopharmaceuticals With Novel Approaches

9:00 am Fireside Chat: Follow the Money- Evolving Co-Opetition in a Competitive Market

  • Kemp Dolliver Director of Research and Senior Analyst, Brookline Capital Markets
  • Vishal Kapur Executive Director - Global Product Strategy and Capabilities, Oncology, Radioligand Therapies, Novartis

Synopsis

  • Fostering dynamics that promote collective strength and stability across the entire sector
  • Supporting initiatives that contribute to the overall growth and resilience of the industry, rather than fostering competition for limited resources- what’s next for radiopharma?
  • Taking more risk in exciting new assets or targets

9:30 am Using Combination Based Approaches to Address Target Heterogeneity, Radio-Resistance & Synergism With Additional Therapeutic Modalities

Synopsis

  • Describing principles of combination therapy for radionuclide therapies
  • Providing methods of improving therapeutic index
  • Presenting prospective data with combination therapy (TRT + other modalities and TRT + TRT)

10:00 am Morning Break & Networking

Discovery & Preclinical

Identifying Novel Targets & Treatment Indications to Uncover Future Therapeutic Potential Across TRPs

11:00 am Next Generation Radiopharmaceuticals: How Good Can We Get?

  • Amos Hedt Chief Business Officer, Perspective Therapeutics

Synopsis

  • Examining what is the current state of the art for radiopharmaceutical therapies
  • Re-evaluating what are the characteristics of the “Ideal” Radiopharmaceutical Therapy
  • Identifying what technologies are available to build such a therapy

11:30 am Roundtables: Exploring Novel Radiopharmaceutical Treatment Modalities: Future Applications & Challenges

Synopsis

  • From NSCLC, Ovarian Cancer, Breast Cancer, Colorectal Cancer & more
  • Outlining the opportunities in each indication
  • Identifying challenges in application

11:45 am CMC Assembly: Academic vs. Industry Approaches

  • Michael Nickels Director, Cyclotron Facility, Washington University School of Medicine

Synopsis

  • Giving an overview of the CMC assembly and submission process will be given with an emphasis on the academic approach 
  • Reviewing major roadblocks experienced between academics and industry 
  • Discussing proposals for the optimization of this process

Early-Stage Clinical

Optimizing Alpha Therapies Through Dosimetry to Enhance Treatment Efficacy

11:00 am Making Successful 212Pb-Targeted Alpha Therapy a Reality

Synopsis

  • Seeking to develop a new generation of targeted therapies against cancer, based on the unique properties of 212Pb
  • Exploring the multi-asset portfolio, including two compounds in clinical development and a diverse pipeline
  • Sharing more about AlphaMedixTM receiving Breakthrough Therapy Designation by the FDA

11:30 am Innovation Spotlight

Synopsis

Your chance to see the latest technologies being applied to early clinical radiopharmaceutical development.

Observe and get to know 3 innovative new solutions in this lightning-round technical demonstration

11:45 am Revealing Pb212-based TAT for Enhanced Drug Development

Synopsis

  • Uncovering methods for Pb212 PSMA SPECT CT imaging
  • Using Pb212 PSMA dosimetry to inform dosing
  • Revealing the Advancell pipeline

Late-Stage Clinical

Future Thinking for TRPs: Fine Tuning the Landscape

11:00 am PSMA RLT: Post-Approval Optimization

  • Amir Iravani Associate Professor, University of Washington- Fred Hutchinson Cancer Center, Seattle, WA

Synopsis

  • Optimal patient selection and predictive and prognostic biomarkers
  • Treatment schedule and modification
  • Response monitoring, dynamic risk stratification, and retreatment

11:30 am Innovation Spotlight

Synopsis

Your chance to see the latest technologies being applied to early clinical radiopharmaceutical development.

Observe and get to know 3 innovative new solutions in this lightning-round technical demonstration

11:45 am SAR-bisPSMA: Latest Updates on Next Generation Theranostics in Prostate Cancer

Synopsis

  • Demonstrating robust therapeutic safety profile
  • Revealing enhanced imaging
  • Explore future perspectives for SAR-bisPSMA

12:15 pm Lunch Break & Networking

Discovery & Preclinical

Using Novel Tools & Technologies to Transform Radiopharmaceutical Development

1:15 pm Uncovering Novel Microenvironmental Targets for Radiopharmaceutical Development

  • Daniel Thorek Professor, Washington University School of Medicine in St. Louis

Synopsis

  • Targeting stromal cells in tumor and metastatic masses, attractive targets for radiopharmaceutical ablation
  • Evaluating a novel high affinity antibody platform targeting LRRC15 in preclinical systems
  • Exploring cross reaction with humans for targeted imaging and therapy of aggressive treatment refractory cancers of mesenchymal lineage

1:45 pm Revealing Host-Guest Pretargeting for Image-guided Targeted Radionuclide Therapy

Synopsis

  • Exploring radiotherapeutic effect
  • Outlining theranostic potential in ovarian cancer
  • Looking at organ dose and tumor uptake 

Early-Stage Clinical

Translational Success Through Forward Thinking Nuclear Clinical Design

1:15 pm Update on PSMA-Directed Actinium Labeled Radioantibody Therapy

  • Philip Kantoff Chief Executive Officer & Co-Founder, Convergent Therapeutics

Synopsis

  • Exploring the rationale for using antibodies when targeting PSMA with Actinium-225
  • Uncovering activity of CONV01-a monotherapy in advanced prostate cancer
  • Sharing activity of CONV01- a combination therapies in advanced prostate cancer

1:45 pm Selecting Optimal Clinical Candidates & Keeping Clinical Design Patient Centric

  • Jeremie Calais Director of Theranostics Research Program, University of California Los Angeles

Synopsis

  • Refining patient selection processes as we enter new indications
  • Tools for patient selection
  • Important areas for patient centricity

Late-Stage Clinical

An Evolving Isotope Manufacturing Roadmap: Future Thinking Practices

1:15 pm Panel Discussion: Building Better Radiopharmaceutical Manufacturing Workforces to Streamline Production

  • Ying Cai Director - Supply Chain, Ashvattha Therapeutics
  • Michael Nickels Director, Cyclotron Facility, Washington University School of Medicine

Synopsis

  • Exploring recruitment and training
  • Using academic collaboration
  • Providing cross-training opportunities

1:45 pm Exploring Lessons From Managing Regulations for Radiopharmaceutical Manufacturing

  • Mike Wardach Senior Regulatory Sciences Advisor, Telix Pharmaceuticals

Synopsis

  • Adhering to regulatory guidelines
  • Optimizing tech transfer
  • Exploring stakeholder relationships

2:15 pm Afternoon Break & Networking

The Future of Radiopharmaceutical Development: Personalized Therapies & Next-generation Targets

2:45 pm Reporting Data from Personalized Clinical Trials & Examining Impact on Efficacy

  • Jeremie Calais Director of Theranostics Research Program, University of California Los Angeles

Synopsis

  • Looking at trial data to learn the impact of personalized approaches
  • How could this be implemented long term
  • Exploring future potential

3:15 pm Revealing Novel Radiopharmaceutical Target CA IX & new Molecules in Radiopharmaceutical Development

Synopsis

  • Exploring future applications for CA9
  • Outlining targeting approaches
  • Selecting optimal radioisotopes

3:45 pm Chair’s Closing Remarks

3:55 pm End of Conference